Author: Boston ScientificPublished: 16 January 2020
Prep: Cook: Serves:
We hear from four experts in the field of Parkinson’s
on why global collaboration is vital to advancing deep brain stimulation (DBS) –
and achieving better treatment results for patients
Leading neurosurgeons and neurologists from around the world came together last year for an international meeting organised by Boston Scientific in Porto, Portugal, to share their expertise on deep brain stimulation (DBS) – an established therapy for people with Parkinson’s.
The event brought together more than 70 specialists from around the world. We managed to speak to four experts to learn from them about how global collaboration is leading to medical breakthroughs, their hopes and predictions for the future of the treatment – and what it all means for people with Parkinson’s.
Improving Parkinson’s treatments through global collaboration
Collaborating with a global network of peers is a
fundamental step in developing DBS, explains
Katsuo Kimura, an assistant professor of neurology at Yokohama City
University, Japan: “Collaboration is key to future medical breakthroughs
because medical systems and information are different in each country – so it’s
an important way to break those barriers, share our knowledge, and improve our
countries’ clinical activities.
“The number of people diagnosed with Parkinson’s is
increasing in every country. However, the number of patients who receive DBS in
each country is still limited. If we discuss our findings in person, like here
in Porto at the DBS Academy, we can achieve medical breakthroughs more rapidly.”
Andrea Kuhn, a consultant and professor of neurology at
Charite Universitatsmedizin, Germany, adds: “The DBS Academy in Porto is a very
specific meeting on DBS. It’s an important exchange on new technical advances
and clinical studies on the therapy. It’s a relatively small meeting, so we take
the opportunity to sit together and discuss our projects – and that really
It’s through this sharing of knowledge that the medical
community is able to improve available treatment for people with Parkinson’s,
explains Rui Vaz, a neurosurgeon at Centro Hospitalar de Sao Joao, Portugal.
“Parkinson’s is different from patient to patient, so it’s very important that DBS continually improves,” says Professor Vaz. “Collaboration is important because we need to go from treating the condition to treating the patient – we need to develop DBS to offer personalised treatment.”
Developing DBS therapy for better results
DBS is a therapy where
two very small electrodes (wires) in the brain are connected to a battery –
also known as a device or pulse generator – under the skin in the chest. The
therapy helps control the motor symptoms of Parkinson’s by delivering
electrical signals into the specific areas of the brain affected.
The therapy is continuously advancing with better outcomes
for people with Parkinson’s, avoiding side effects and targeting specific
symptoms of the condition.
Professor Vaz explains why the development of electrodes, which are placed into the brain during DBS surgery, and the development of batteries, which power the stimulator device, has significantly improved the therapy: “With directional electrodes, we can now steer currents exactly in the direction we want, allowing us to control specific symptoms. And the new small rechargeable batteries in DBS allow us to better regulate the current of the device.”
He continues: “Collaboration was key in achieving these
developments because it required multidisciplinary knowledge. In this case, the
partnership between medicine and engineering was essential for the development of
new technology that is helping us to better treat people with Parkinson’s.”
Professor Kuhn adds that directional lead technology,
where “the two middle contacts of the DBS device are segmented into three
smaller contacts so that the device can direct the current much better”, is a significant
advance. This new technology, she explains, “reduces side effects that can
occur when the current is too high, or the electrodes are not perfectly in the
area where we would like to place them”.
“There’s also the improvement in using the telemetry – the
handheld devices for the patient – which are now smaller and easier to handle,”
A bright future ahead for DBS
A specialist in the field of gait disorders, Carine Karachi, professor in neurosurgery at University Hospitals Pitie Salpetriere, France, hopes in the near future to tailor DBS to specifically alleviate freezing of gait – a symptom of Parkinson’s where walking is suddenly impaired.
disorders remain one of the main motor disabilities in Parkinson’s,” says
Professor Karachi. “We’re starting a new trial next year using directional DBS electrodes
into the area of the brain called the subthalamic nucleus to see if steering
current can alleviate freezing of gait.
to stimulate specific spots that we know are connected to gait disorders from
studying the data of 300 patients. We also plan to collaborate with experts in Canada to build a template
with data on targeting to alleviate gait because sharing our experience and
results will improve DBS therapy for patients.”
Vaz notes that as the therapy advances, its offerings will also expand: “I’m
very excited about DBS’s potential to treat other neurological conditions. We
would very much like to better understand the connections between different
circuits of the brain and be able to develop DBS in the treatment of other
conditions, for example psychiatric conditions like depression and anorexia.”
Kuhn says there are many opportunities to enhance DBS and shares her vision of
indivualised treatments for people with Parkinson’s.
“Parkinson’s is not the same in every patient or the same at every hour of the day,” she says. “That’s the biggest challenge. For example, we may need specific therapy for tremor dominant Parkinson’s in comparison to a patient that suffers more from dyskinesia. DBS is still not a perfect therapy, and it’s always important to improve. What we really look forward to is individualised DBS therapy that can be adjusted to the patients’ needs throughout each day.”
Frequently asked questions
Is DBS a magic tool?
Professor Carine Karachi says: “I’m always a bit worried that people think DBS is a magic tool. Sometimes it is; sometimes the expectations are too high compared to what DBS can do. So, I tell them DBS doesn’t cure Parkinson’s, but it does alleviate symptoms remarkably.”
Is DBS surgery painful?
Professor Rui Vaz says: “In our hospital we perform the surgery while the patient is awake. One of the essential questions that many people ask us is if they will suffer during the procedure. Based on my experience I assure them and explain that they will feel no pain.”
When is the right time for DBS therapy?
Professor Katsuo Kimura says: “In Japan, when a patient develops motor fluctuations, they often ask me if it’s the right time to receive DBS therapy. I always answer: ‘The time is now’. DBS is not a last-resort therapy, it’s an established treatment option for advanced Parkinson’s patients.”
Achieving excellent results around the world with DBS
We asked the four professors – who have treated hundreds of people with Parkinson’s during their longstanding careers working with DBS – to share the best outcomes they’ve seen.
Professor Katsuo Kimura says: “One young man developed very severe dyskinesia and it interrupted his work. He was managing his dyskinesia with
medication, which he took five or six times a day. After having DBS therapy, he has now reduced the frequency of his medication and his dyskinesia has disappeared. He can work full time again and he’s very happy.”
Professor Andrea Kuhn says: “Many people we see have young onset Parkinson’s in their 40s or 50s. They have severe motor fluctuations and dyskinesia and with the help of DBS, they can go back to a normal life. They can start going out again, pursue their hobbies and continue to work. So that’s always a very positive experience of DBS because it really changes the lives of patients.”
Professor Rui Vaz says: “One woman had severe Parkinson’s and the DBS therapy worked really well for her. Two years ago, there was a terrible fire in Portugal in the area where she lived, and it killed 60 people. Our patient was able to run away and take her elderly mother with her. The house was completely destroyed but they managed to save themselves, which I think is incredible.”
For more information on DBS please visit Parkinson’s Europe website and the Boston Scientific website and Twitter page.
This article is sponsored by Boston Scientific. The information in this article is given for information purposes only and does not represent an endorsement by Parkinson’s Europe of any particular treatments, products or companies. This article is not a substitute for advice from your doctor, pharmacist or other healthcare professional. Parkinson’s Life makes no representations or warranties of any kind, express or implied, about the completeness or accuracy of information provided.
Aspiring Parkinson’s nurses urged to apply for “hands-on” summer school in Portugal
A unique opportunity to bring Parkinson’s nurses together
4 weeks ago
Parkinson’s Europe co-founder Lizzie Graham wins World Parkinson Coalition award
Parkinson’s Europe co-founder Lizzie Graham has won a World Parkinson Coalition (WPC) award for her contribution to the Parkinson’s community. Lizzie is one of four people set to receive the Robin Elliott Award – which is given out every three years to individuals whose efforts best embody the goals and ethos of the WPC. She will be presented with the award in a ceremony at the World Parkinson’s Congress, which will be held in Barcelona later this year. Commenting on the news of Lizzie’s award, Parkinson’s Europe President, Veronica Clark, said: “Lizzie is Lizzie, and we love her for who she is and what she has done for us all – for people with Parkinson’s past and present and, I’m sure, future.” Lizzie co-founded the European Parkinson’s Disease Association (renamed Parkinson’s Europe last year) in 1992. She has since held several roles within the organisation – including secretary general and…
Study explores predictors of cognitive impairment in Parkinson’s disease
Cognitive impairment can affect some people with Parkinson’s – and may greatly impact their quality of life. Now, researchers in China have examined the possible risk factors for cognitive impairment in those with the condition. The study analysed data from 409 people with Parkinson’s within two years of their involvement in the Parkinson’s Progression Markers Initiative (PPMI) – an international study that follows people with and without the condition over time. The participants, who were newly diagnosed and experiencing normal cognitive function at the start of the research, were studied for at least five years. Published in ‘Frontiers in Aging Neuroscience’, the results indicate that older age at onset, high blood pressure and worse baseline motor symptoms may be among factors that could contribute to an increased risk of developing cognitive impairment. The researchers cautioned that “a larger sample and much more comprehensive assessment, and prolonged follow-up, will be required”.
Could frailty be a potential risk factor for Parkinson’s disease?
Frailty can refer to a reduction in physical function, and its attributes – including a slow walking speed and weak grip – are commonly experienced by people with Parkinson’s. Until now, there has been limited insight into the link between frailty and the risk of developing the condition over time. This is what led researchers at the Huazhong University of Science and Technology in China to analyse data from a large UK study, which was gathered over a 12-year period. Published in JAMA Neurology, the analysis found that frailty may be linked to an 87% higher risk of developing the condition. Commenting on the results, the researchers said: “These findings indicate that physical frailty is a potential risk factor for [Parkinson’s], and the assessment and management of frailty might have clinical significance in the at-risk population.”